Behind the Paper: How IL-6 shapes the anti-tumor battle and supports TGFβ immune modulatory vaccines in pancreatic cancer
The study highlights that the antitumor efficacy of TGFβ-specific T cells in pancreatic cancer critically depends on IL-6 signaling. IL-6R blockade compromises the immune response by reducing vaccine-induced T-cell infiltration as well as increasing immunosuppressive tumor-associated macrophages.
TSLPR CAR T-cell therapy: A new hope for CRLF2+ ALL, but timing of JAK inhibition is crucial
Acute lymphoblastic leukemia (ALL) with CRLF2 rearrangements in Ph-like and Down syndrome-associated ALL subtypes poses a significant challenge in pediatric oncology. These genetic abnormalities lead to constitutive signaling activation and induce resistance to conventional chemotherapy.
Exploring Socioeconomic Disparities in Diffuse Large B-Cell Lymphoma Survival in Germany: A Nationwide Study
What role does socioeconomic deprivation play in the survival of patients with diffuse large B-cell lymphoma?
Uncovering distinct genomic and molecular signatures in triple-negative inflammatory breast cancer
This study is the most comprehensive genomic and transcriptomic analysis of triple-negative inflammatory breast cancer (TN-IBC) patient samples, uncovering unique genetic and immune characteristics. These findings aim to advance the diagnosis and treatment of this aggressive disease.
Dissecting the natural history of IDH-mutant gliomas
Our work reveals that as IDH mutant gliomas progress, their cell states and key drivers change.
Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization
Activating the mevalonate (MVA) pathway increases bladder cancer (BLCA) spread. High MVA enzyme levels predict worse outcomes. Drugs like zoledronic acid or simvastatin blocking this pathway reduce cancer cell migration by affecting the protein RhoB. Targeting the MVA pathway could help treat BLCA.
